The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas

Abstract EN

Despite the fact that the majority of lymphomas initially respond to treatment, many patients relapse and die from disease that is refractory to current regimens.

The need for new treatment strategies in lymphomas has led to the investigation and evaluation of novel agents that target cellular pathways.

The mammalian target of rapamycin (mTOR) is a representative pathway that may be implicated in lymphomagenesis.

Rapamycin and especially its derivatives (temsirolimus, everolimus, and deforolimus) represent the first described mTOR inhibitors.

These agents have shown promising results in the treatment of lymphoid malignancies.

On the other hand, new ATP-competitive mTOR inhibitors that provoke a broader inhibition of mTOR activity are in early stages of clinical development.

The purpose of this paper is to summarize the existing knowledge about mTOR inhibitors and their use in the treatment of B-cell lymphomas.

Relevant issues regarding mTOR biology in general as well as in B-cell lymphoid neoplasms are also discussed in short.